Adjuvant anti-VEGF therapy for overall survival and relapse-free survival in patients with resected non-metastatic colorectal cancer

To assess the efficacy and safety of the use of anti-angiogenic agents (VEGF inhibitors) in the adjuvant setting after resection in patients diagnosed with resectable colorectal cancer.
This would permit a summary of the safety and effectiveness of anti-VEGF therapies overall, as well as in pre-planned prognostic subgroups, and identify areas where further research could be directed.

This is a protocol.

Share/Save